<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394211</url>
  </required_header>
  <id_info>
    <org_study_id>11-0269-04</org_study_id>
    <secondary_id>NCI-2011-01114</secondary_id>
    <secondary_id>3P30CA023074</secondary_id>
    <nct_id>NCT01394211</nct_id>
  </id_info>
  <brief_title>Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer</brief_title>
  <official_title>Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before&#xD;
      surgery works in treating patients with stage II-III estrogen receptor-positive breast&#xD;
      cancer. Pazopanib hydrochloride and anastrozole may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride and&#xD;
      anastrozole together before surgery may make the tumor smaller and reduce the amount of&#xD;
      normal cells that have to be removed&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To determine the pathologic complete response (pCR) rate at surgery.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate alternative measurements of anti-tumor activity: proportion of patients&#xD;
      achieving sustained decrease in antigen KI-67 (ki-67) at 12 weeks of therapy with anastrozole&#xD;
      plus pazopanib (pazopanib hydrochloride); proportion of patients achieving down-staging to a&#xD;
      pathologic stage 0 or 1 at surgery.&#xD;
&#xD;
      II. To assess qualitative and quantitative toxicity of this combination, with special&#xD;
      emphasis on the frequency of events grade 3 or greater, or the occurrence of unexpected&#xD;
      toxicities.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive pazopanib hydrochloride* orally (PO) once daily (QD) and anastrozole PO QD&#xD;
      for 6 months in the absence of disease progression or unacceptable toxicity. Patients then&#xD;
      undergo definitive surgery.&#xD;
&#xD;
      NOTE: *Pazopanib hydrochloride is stopped 7-14 days before surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">July 13, 2011</start_date>
  <completion_date type="Actual">April 12, 2012</completion_date>
  <primary_completion_date type="Actual">April 12, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pCR at Primary Site (T0) and Nodal Sites (T0N0)</measure>
    <time_frame>Six months from the initiation of neoadjuvant therapy</time_frame>
    <description>Defined as no evidence of microscopic invasive tumor present. Determined by pathology. Estimated with an exact 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Sustained Decrease in Ki-67</measure>
    <time_frame>12 weeks from the initiation of neoadjuvant therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Down-staging to a Pathologic Stage 0 or 1</measure>
    <time_frame>Six months from the initiation of neoadjuvant therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant enzyme inhibitor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Neoadjuvant enzyme inhibitor therapy</arm_group_label>
    <other_name>ANAS</other_name>
    <other_name>Arimidex</other_name>
    <other_name>ICI-D1033</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Neoadjuvant enzyme inhibitor therapy</arm_group_label>
    <other_name>GW786034</other_name>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo definitive surgery</description>
    <arm_group_label>Neoadjuvant enzyme inhibitor therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must provide written informed consent prior to performance of study-specific&#xD;
             procedures or assessments, and must be willing to comply with treatment and follow-up;&#xD;
             procedures conducted as part of the subject's routine clinical management (e.g., blood&#xD;
             count, imaging study) and obtained prior to signing of informed consent may be&#xD;
             utilized for screening or baseline purposes provided these procedures are within the&#xD;
             protocol determined screening or baseline timeframes, and equivalent to the&#xD;
             specifications in the protocol; also note, a written waiver/approval from the&#xD;
             Investigator/Sponsor is still required&#xD;
&#xD;
          -  Histologically confirmed diagnosis of estrogen receptor-positive (ER+), HER2 negative&#xD;
             breast cancer, with clinical stage II or III disease&#xD;
&#xD;
          -  Stage IIA T0-1 N1 M0, T2 N0 M0, OR&#xD;
&#xD;
          -  Stage IIB T2 N1 M0, T3 N0 M0 OR&#xD;
&#xD;
          -  Stage IIIA T0-2 N2 M0, T3 N1-2 M0, OR&#xD;
&#xD;
          -  Stage IIIB T4 N0-2 M0&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  No evidence of distant metastatic disease&#xD;
&#xD;
          -  Baseline Oncotype DX score of 29 or lower; patients with known Oncotype DX recurrence&#xD;
             score (RS) of 30 or greater are not eligible&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Hemoglobina &gt;= 10 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7&#xD;
             days of screening assessment&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Prothrombin time (PT) or international normalized ratio (INR) =&lt; 1.2 x upper limit of&#xD;
             normal (ULN); subjects receiving anticoagulant therapy are eligible if their INR is&#xD;
             stable and within the recommended range for the desired level of anticoagulation&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) =&lt; 1.2 x ULN&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN;&#xD;
             concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN is not permitted&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL (133 umol/L) or, if &gt; 1.5 mg/dL: calculated creatinine&#xD;
             clearance (CLCR) &gt;= 50 mL/min&#xD;
&#xD;
          -  Urine protein to creatinine ratio (UPC) &lt; 1; if UPC &gt;= 1, then a 24-hour urine protein&#xD;
             must be assessed; subjects must have a 24-hour urine protein value &lt; 1 g to be&#xD;
             eligible&#xD;
&#xD;
          -  A female is eligible to enter and participate in this study if she is:&#xD;
&#xD;
          -  Is post-menopausal&#xD;
&#xD;
          -  Subjects not using hormone replacement therapy (HRT) must have experienced total&#xD;
             cessation of menses for &gt;= 1 year and be greater than 45 years in age, OR, in&#xD;
             questionable cases, have follicle stimulating hormone (FSH) value &gt; 40 mIU/mL and an&#xD;
             estradiol value &lt; 40 pg/mL (&lt; 140 pmol/L)&#xD;
&#xD;
          -  Subjects using HRT must have experienced total cessation of menses for &gt;= 1 year and&#xD;
             be greater than 45 years of age OR have had documented evidence of menopause based on&#xD;
             FSH and estradiol concentrations prior to initiation of HRT; patients will be required&#xD;
             to be off of HRT for at least 2 weeks prior to initiating therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignancy; note: subjects who have had another malignancy and have been&#xD;
             disease-free for &gt;= 5 years, or subjects with a history of completely resected&#xD;
             non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible&#xD;
&#xD;
          -  Known distant metastases at any site; history or clinical evidence of central nervous&#xD;
             system (CNS) metastases or leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities that may increase the risk for&#xD;
             gastrointestinal bleeding including, but not limited to:&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
&#xD;
          -  Known intraluminal metastatic lesion/s with risk of bleeding&#xD;
&#xD;
          -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or&#xD;
&#xD;
          -  Other gastrointestinal conditions with increased risk of perforation&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 28 days of registration to the study; clinically significant gastrointestinal&#xD;
             abnormalities that may affect absorption of investigational product including, but not&#xD;
             limited to:&#xD;
&#xD;
          -  Malabsorption syndrome&#xD;
&#xD;
          -  Major resection of the stomach or small bowel&#xD;
&#xD;
          -  Presence of uncontrolled infection&#xD;
&#xD;
          -  Corrected QT interval (QTc) &gt; 480 msecs using Bazett's formula&#xD;
&#xD;
          -  History of any one or more of the following cardiovascular conditions within 6 months&#xD;
             of registration on the study:&#xD;
&#xD;
          -  Cardiac angioplasty or stenting&#xD;
&#xD;
          -  Myocardial infarction&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Coronary artery bypass graft surgery&#xD;
&#xD;
          -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  Class III or IV congestive heart failure, as defined by the New York Heart Association&#xD;
             (NYHA)&#xD;
&#xD;
          -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of &gt;= 140&#xD;
             mmHg or diastolic blood pressure (DBP) of &gt;= 90 mm Hg]; note: initiation of adjustment&#xD;
             of antihypertensive medication(s) is permitted prior to study entry&#xD;
&#xD;
          -  History of cerebrovascular accident including transient ischemic attack (TIA),&#xD;
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months&#xD;
             of registration on the study; note: subjects with recent DVT who have been treated&#xD;
             with therapeutic anti-coagulating agents for at least 6 weeks of registration to the&#xD;
             study are eligible&#xD;
&#xD;
          -  Prior major surgery or trauma within 28 days of registration on the study prior to&#xD;
             first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer&#xD;
             (procedures such as catheter placement not considered to be major)&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
          -  Hemoptysis within 8 weeks of registration to the study&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
             could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
             study procedures&#xD;
&#xD;
          -  Treatment with any of the following anti-cancer therapies for the current diagnosis of&#xD;
             stage 2-3 estrogen positive breast carcinoma:&#xD;
&#xD;
          -  Radiation therapy, surgery or tumor embolization within 14 days prior to first dose of&#xD;
             pazopanib OR&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal&#xD;
             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the&#xD;
             first dose of pazopanib&#xD;
&#xD;
          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt; Grade 1 and/or that is&#xD;
             progressing in severity, except alopecia&#xD;
&#xD;
          -  Concomitant anti-cancer therapies are not permitted&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Pazopanib or Anastrozole used in the study&#xD;
&#xD;
          -  Concomitant use of medications or substances that are inhibitors or inducers of strong&#xD;
             CYP3A4 inhibitors are ineligible&#xD;
&#xD;
          -  Concomitant: the concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole,&#xD;
             ritonavir, clarithromycin) may increase pazopanib concentrations and should be&#xD;
             avoided; if coadministration of a strong CYP3A4 inhibitor is warranted, reduce the&#xD;
             dose of pazopanib to 400 mg; further dose reductions may be needed if adverse effects&#xD;
             occur during therapy; this dose is predicted to adjust the pazopanib AUC to the range&#xD;
             observed without inhibitors; however, there are no clinical data with this dose&#xD;
             adjustment in patients receiving strong CYP3A4 inhibitors; grapefruit juice should be&#xD;
             avoided as it inhibits CYP3A4 activity and may also increase plasma concentrations of&#xD;
             pazopanib&#xD;
&#xD;
          -  Concomitant strong CYP3A4 inducer: the concomitant use of strong CYP3A4 inducers (e.g.&#xD;
             rifampin) may decrease pazopanib concentrations and should be avoided&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Livingston</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>July 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2018</results_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Through physician</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Neoadjuvant Enzyme Inhibitor Therapy</title>
          <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.&#xD;
anastrozole: Given PO&#xD;
pazopanib hydrochloride: Given PO&#xD;
therapeutic conventional surgery: Undergo definitive surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neoadjuvant Enzyme Inhibitor Therapy</title>
          <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.&#xD;
anastrozole: Given PO&#xD;
pazopanib hydrochloride: Given PO&#xD;
therapeutic conventional surgery: Undergo definitive surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of pCR at Primary Site (T0) and Nodal Sites (T0N0)</title>
        <description>Defined as no evidence of microscopic invasive tumor present. Determined by pathology. Estimated with an exact 95% confidence interval.</description>
        <time_frame>Six months from the initiation of neoadjuvant therapy</time_frame>
        <population>Participants withdrew from participation</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Enzyme Inhibitor Therapy</title>
            <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.&#xD;
anastrozole: Given PO&#xD;
pazopanib hydrochloride: Given PO&#xD;
therapeutic conventional surgery: Undergo definitive surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of pCR at Primary Site (T0) and Nodal Sites (T0N0)</title>
          <description>Defined as no evidence of microscopic invasive tumor present. Determined by pathology. Estimated with an exact 95% confidence interval.</description>
          <population>Participants withdrew from participation</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Sustained Decrease in Ki-67</title>
        <time_frame>12 weeks from the initiation of neoadjuvant therapy</time_frame>
        <population>Participants withdrew from participation</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Enzyme Inhibitor Therapy</title>
            <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.&#xD;
anastrozole: Given PO&#xD;
pazopanib hydrochloride: Given PO&#xD;
therapeutic conventional surgery: Undergo definitive surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving Sustained Decrease in Ki-67</title>
          <population>Participants withdrew from participation</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Down-staging to a Pathologic Stage 0 or 1</title>
        <time_frame>Six months from the initiation of neoadjuvant therapy</time_frame>
        <population>Participants withdrew from participation</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Enzyme Inhibitor Therapy</title>
            <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.&#xD;
anastrozole: Given PO&#xD;
pazopanib hydrochloride: Given PO&#xD;
therapeutic conventional surgery: Undergo definitive surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving Down-staging to a Pathologic Stage 0 or 1</title>
          <population>Participants withdrew from participation</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Nine months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant Enzyme Inhibitor Therapy</title>
          <description>Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.&#xD;
NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery.&#xD;
anastrozole: Given PO&#xD;
pazopanib hydrochloride: Given PO&#xD;
therapeutic conventional surgery: Undergo definitive surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Coordinator</name_or_title>
      <organization>University of Arizona Cancer Center</organization>
      <phone>5206260301</phone>
      <email>aselegue@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

